Sarbanes-Oxley Act of 2002 2005 Agenda Getting Started Scoping The COSO Environment Anti-Fraud Controls Internal Control Questionnaires Documentation Testing Evaluation of Internal Control Deficiencies and Reporting Geller & Company and You
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
The scoping process is used to identify the significant accounts, disclosures, business processes/cycles and locations that must be documented and tested.
The documentation produced in the Section 404 project forms the basis and support for management’s evaluation of internal control over financial reporting. Further, the SEC’s final rules on Section 404 indicate that it is a company’s responsibility to document internal control and that developing and maintaining such documentation is inherent to effective internal control.
To demonstrate effective internal control over financial reporting, management should determine whether the company’s controls are operating effectively. This requires testing the controls. The company must retain evidence of this testing to support management’s assessment of internal control over financial reporting.
Evaluating the significance of internal control deficiencies and reporting is an evolving area that will require a significant degree of management judgment. Control deficiencies can range from internal control deficiencies to significant deficiencies to material weaknesses in internal control.
Information & Communication
5 Pages Total
*Based on the “Framework for Evaluating Control Deficiencies, Version 3 (issued 12/20/04)”
Office Location:800 Third Avenue 19th Floor New York, New York 10022 (212) 583-6000
Gary Berrigan – A senior member of Geller & Company’s Emerging Business Group. Gary will be the project leader for this engagement. As project manager of Sarbanes Oxley, Gary manages new engagements for Geller & Company ensuring that their clients are in compliance with the Sarbanes-Oxley Act. Some of his experience includes serving as Global Coordinator and Manager of Internal Controls for a subsidiary of a billion dollar Fortune 500 Company ensuring compliance with the Sarbanes-Oxley Act, Director of Fraud Investigations for a global Life Insurance Company and 10 years as a Financial Analyst with the Federal Bureau of Investigation. He is skilled in evaluating the internal control environment of companies for compliance with the Sarbanes-Oxley Act both within the United States and Internationally as well as performing Sarbanes Oxley readiness training and implementation. Gary will be responsible for the day-to-day execution of all phases for the Company.
Michael Bernstein – Leads the Emerging Business Group for Geller & Company and will serve as an overall relationship manager. Mike has more than 22 years of experience working with public and private companies. Prior to joining Geller & Company, Mike was a partner with Grant Thornton LLP where he served in senior positions, including SEC partner for the New York Area offices. He is also a board member and audit committee chair for Bradley Pharmaceuticals, a NYSE publicly traded company. Mike will work with the client service team to develop the plan, review the results and present our deliverables. He has served on panels at numerous venture and industry conferences, has been quoted in Business Finance Magazine (on the Sarbanes-Oxley Act), Forbes.com (on Corporate Governance matters), the Venture Capital Journal and Business Week and co-authored the book Raising Capital, published by Business Irwin Professional Publishing. In his role as Audit Committee Chairman Mike has ongoing responsibility for Bradley Pharmaceuticals’ compliance with the Sarbanes-Oxley Act.